Greenwich, Connecticut, November 9, 2010 – Scrip, a leading global pharmaceutical and biotech news organization, recognized Aptuit and Exelixis for excellence in partnership with a 2010 Scrip Award for collaboration around Exelixis’ lead oncology programs.

“Aptuit is honored to be recognized by such a highly respected industry organization for our work with Exelixis,” commented Timothy C. Tyson, chairman and chief executive officer at Aptuit. “The market for integrated outsourced drug development services continues to grow and evolve, and this award confirms Aptuit’s leadership role with our ability to help our customers with some of their toughest challenges. Recognition in the area of outsourcing partnership by our industry peers, against some significant competition on the night of the awards, is truly a credit to the teams from both sides of this partnership establishing such a highly functioning and productive model of working together to advance important drug compounds, and it is representative of the outstanding partnerships we’ve cultivated across our organization.”

Since 2006, Aptuit has supported Exelixis on five different development programs, including Exelixis’ late-stage candidate for metastatic medullary thyroid cancer, providing drug development and manufacturing, analytical testing and validation, and clinical packaging and distribution services.

“The successful partnership with Aptuit is a critical part of our preparation for the commercialization of our lead compound, XL184,” said Michael Morrissey, President and CEO of Exelixis, Inc. “They are a strong partner that augments our internal capacity and provides unique insights and capabilities.”